ABSTRACT
BACKGROUND: Synaptotagmin 7 (SYT7) is a component of the synaptotagmin family, which is essential in many physiological and pathological processes. In this study, we aimed to investigate the role of SYT7 in osteosarcoma. METHODS: We defined the expression levels of SYT7 in osteosarcoma tissues and para-sarcoma tissues by immunohistochemistry and analyzed the possible correlation between SYT7 expression and pathological characteristics via Mann-Whitney U analysis and Spearman correlation analysis. The effects of SYT7 silencing in vitro cell growth were assessed by MTT assay. Cell cycle and cell apoptosis were assessed by flow cytometry analysis. Wound healing assay and transwell assay were applied to assess the migration and invasion capacity. RESULTS: The results showed that the expression levels of SYT7 were upregulated in osteosarcoma tissues compared with para-sarcoma tissues and positively correlated with the pathological characteristics of osteosarcoma. Functional experiments demonstrated that SYT7 silencing significantly inhibited cell proliferation and colony formation capacity (P<0.001), induced cell cycle arrest which increased the proportion of G2 phase and decreased the proportion of S phase, enhanced cell apoptosis (P<0.01), and limited the capacity of migration and invasion (P<0.01), compared with shCtrl group. CONCLUSION: The results indicated that SYT7 plays a crucial role in the development of osteosarcoma. SYT7 can be applied as a new diagnostic and therapeutic target in osteosarcoma.
Subject(s)
Bone Neoplasms/metabolism , Gene Silencing , Osteosarcoma/metabolism , Synaptotagmins/metabolism , Adult , Apoptosis , Bone Neoplasms/genetics , Cell Cycle , Cell Line, Tumor , Cell Movement , Cell Proliferation , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Neoplasm Invasiveness , Osteosarcoma/genetics , RNA Interference , Synaptotagmins/genetics , Wound HealingABSTRACT
Previous studies have evaluated the accuracy of serum and urinary measurements of cytokeratin-19 fragment (CYFRA 21-1) for the diagnosis of bladder cancer; however, the results have been inconsistent. The aim of this study was to evaluate the overall accuracy of CYFRA 21-1 for the diagnosis of bladder cancer. We performed a search for English-language publications reporting on the detection of CYFRA21-1 levels for the diagnosis of bladder cancer through November 2, 2014, using public medical databases, including EMBASE, Web of Science, and Medline. The quality of the studies was assessed by revised QUADAS tools. The performance characteristics were pooled and analyzed using a bivariate model. Publication bias was explored with the Deek's test. Sixteen studies, with a total 1,262 bladder-cancer patients and 1,233 non-bladder-cancer patients, were included in the study. The pooled sensitivities for serum and urine CYFRA 21-1 were 0.42 (95 % confidence interval (CI), 0.33-0.51) and 0.82 (95 % CI, 0.70-0.90), respectively. The corresponding specificities were 0.94 (95 % CI, 0.90-0.96) and 0.80 (95 % CI, 0.73-0.86), respectively. The areas under the summary receiver-operating-characteristic curves for serum and urine CYFRA 21-1 were 0.88 (95 % CI, 0.85-0.91) and 0.87 (95 % CI, 0.84-0.90), respectively. The major design deficiencies of the included studies were participant-selection bias, potential review, and verification bias. Therefore, we concluded that both serum and urine CYFRA 21-1 served as efficient indexes for bladder-cancer diagnosis. Additional, well-designed studies should be performed to rigorously evaluate the diagnostic value of CYFRA 21-1 for bladder cancer.